CM
TGTX icon

Capula Management’s TG Therapeutics TGTX Stock Holding History

Capula Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-83,997
Closed -$1.43M – 594
2023
Q4 		$1.43M Buy
+83,997
New +$976K 0.06% 65
2023
Q1 		– Sell
-134,060
Closed -$1.59M – 925
2022
Q4 		$1.59M Buy
+134,060
New +$973K 0.02% 347
2021
Q3 		– Sell
-8,478
Closed -$329K – 1054
2021
Q2 		$329K Buy
+8,478
New +$333K 0.01% 555

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capula Management's TGTX Position: Q1 2024 in Review

Capula Management sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 83,997 shares — an estimated $1.43M sold.

Capula Management first reported a position in TGTX in Q2 2021 and held it in 3 quarters. The position peaked at $1.59M in Q4 2022. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Capula Management reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Capula Management sold 83,997 TG Therapeutics shares in Q1 2024, an estimated $1.43M.
  • Capula Management first reported a position in TG Therapeutics in Q2 2021 and held it in 3 quarters.
  • Capula Management's TG Therapeutics position peaked at $1.59M in Q4 2022.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Capula Management's 13F filing for Q1 2024, filed 9 May 2024.